Treatment for Latent TB
For most patients with latent tuberculosis infection, the preferred first-line treatment is 3 months of once-weekly isoniazid plus rifapentine (3HP regimen), which offers the best combination of efficacy, tolerability, and completion rates. 1
Preferred Treatment Regimens (in order of priority)
The 2020 CDC/NTCA guidelines establish a clear hierarchy of treatment options 1:
1. 3 Months of Isoniazid + Rifapentine Once Weekly (3HP)
- Strong recommendation with moderate-quality evidence
- 12 doses total given once weekly
- Can be directly observed or self-administered
- Reduces TB disease risk by 64% compared to no treatment (OR 0.36) 1
- Highest completion rates in clinical practice, particularly when patients have good access to clinicians for side effect management 2
- Key caveat: Associated with systemic drug reactions (flu-like syndrome, syncope, hypotension) in some patients—requires patient education upfront 1
- Requires taking 10 pills simultaneously (vs. 2-3 daily for other regimens)
2. 4 Months of Daily Rifampin (4R)
- Strong recommendation for HIV-negative patients (moderate evidence)
- No evidence available for HIV-positive persons
- Noninferior effectiveness to 9 months isoniazid
- Lower hepatotoxicity and higher completion rates than isoniazid 1
- Particularly useful when isoniazid or pyrazinamide cannot be tolerated 3
- Major limitation: Significant drug-drug interactions (warfarin, oral contraceptives, antiretrovirals)
3. 3 Months of Daily Isoniazid + Rifampin (3HR)
- Conditional recommendation (very low evidence for HIV-negative; low evidence for HIV-positive)
- Similar efficacy to 6-9 months of isoniazid monotherapy 1
- Less hepatotoxicity than longer isoniazid regimens 1
- Important warning: Hepatotoxicity risk may be greater with two drugs combined than either alone 1
- Same drug interaction concerns as rifampin monotherapy
Alternative Regimens
6 Months of Daily Isoniazid (6H)
- Strong recommendation for HIV-negative patients; conditional for HIV-positive
- Reduces TB risk by 60% (OR 0.40) 1
- Longer treatment duration = lower completion rates
- Higher hepatotoxicity risk, especially in adults
- Can be given twice weekly as directly observed therapy 3
9 Months of Daily Isoniazid (9H)
- Conditional recommendation for all patients
- Historically the gold standard with 70-90% protective efficacy 3
- Specifically recommended for:
- Lowest completion rates due to duration
- Monthly monitoring required for hepatotoxicity
Special Population Considerations
HIV-Positive Patients
- 3HP regimen is preferred 1
- If using isoniazid monotherapy, 9 months is required (not 6) 3
- For high TB exposure risk: consider isoniazid for 36 months or longer 4
- Must check antiretroviral drug interactions with rifamycins 1
Children and Adolescents
- 9 months of isoniazid remains the only regimen with established pediatric efficacy data 3
- 3HP and 4R are acceptable alternatives based on adult data 1
- Pyridoxine supplementation needed for breastfeeding infants and those with dietary deficiencies 3
- Hepatotoxicity risk is minimal in children 3
Pregnant Women (HIV-negative)
- Isoniazid 6-9 months is recommended 3
- For high-risk women (HIV-positive, recent infection): do not delay treatment even in first trimester 3
- For lower-risk women: some experts recommend waiting until after delivery 3
Drug-Resistant Exposure
- Isoniazid-resistant, rifampin-susceptible: Rifampin + pyrazinamide for 2 months OR rifampin alone for 4 months 3
- Multidrug-resistant (INH + RIF resistant): Pyrazinamide + ethambutol OR pyrazinamide + fluoroquinolone for 6-12 months 3
- Immunocompetent: treat ≥6 months
- Immunocompromised: treat 12 months
Patients on TNF-α Antagonists
- 3HR or 3HP regimen preferred 4
- 6H can be used if contraindications to combination therapy exist 4
- Timing: Start TPT 4 weeks before TNF-α antagonist in non-urgent situations; can give concomitantly in emergencies 4
Dialysis Patients
- 6H regimen preferred 4
- Hemodialysis: administer medications after dialysis completion 4
- Peritoneal dialysis: regular dosing, timing not affected 4
Critical Pre-Treatment Requirements
Before initiating any LTBI treatment, active TB MUST be ruled out through 3:
- History and physical examination
- Chest radiography
- Bacteriologic studies when indicated
Monitoring Requirements
- Isoniazid or rifampin monotherapy: Monthly clinical evaluation 3
- Rifampin + pyrazinamide: Evaluation at weeks 2,4, and 8 3
- Assess for hepatitis symptoms and signs at each visit
- Baseline laboratory testing is NOT routinely indicated unless initial evaluation suggests liver disorder 3
- Educate patients to stop treatment immediately and seek evaluation if side effects occur 3
Common Pitfalls to Avoid
- Do not use 2 months rifampin + pyrazinamide routinely—this regimen was previously recommended but is no longer preferred due to hepatotoxicity concerns
- Do not forget drug interactions with rifamycins—check all medications, especially antiretrovirals, warfarin, and oral contraceptives
- Do not use 6 months isoniazid in HIV-positive patients—they require 9 months minimum
- Do not skip active TB exclusion—treating active TB with LTBI regimens risks drug resistance
- Do not assume completion equals adherence—shorter regimens have superior real-world effectiveness due to higher completion rates 2
The shift toward shorter rifamycin-based regimens reflects the reality that treatment completion is as important as regimen efficacy for population-level TB control 2, 5.